Antiva Biosciences logo

Antiva Biosciences Funding & Investors

South San Francisco, CA

Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. They aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV.

antivabio.com

Total Amount Raised: $140,346,016

Antiva Biosciences Funding Rounds

  • Series E

    $53,000,000

    Series E Investors

    MPM BioImpact
    Adjuvant Capital
    Sofinnova
    Canaan Partners
    GV
    Lumira Capital Investment Management
    HBM Partners
  • Series D

    $31,000,000

    Series D Investors

    Adjuvant Capital
    Dong-A ST Co.
    Brace Pharma Capital
    Osage University Partners (OUP)
    Sirona Capital
    Gaingels
    Lumira Capital Investment Management
    GV
    Mana Ventures
    Canaan Partners
    Sofinnova
    Alexandria Venture Investments
    HBM Healthcare Investments
    Avestria Ventures
  • Series C

    $15,000,000

    Series C Investors

    Hillhouse Capital
    Sirona Capital
    Osage University Partners (OUP)
    Sofinnova
    Brace Pharma Capital
    Canaan Partners
    JLABS
    NS Investment
    Alexandria Venture Investments
  • Series C

    $22,000,000

    Series C Investors

    Brace Pharma Capital
    NS Investment
    Osage University Partners (OUP)
    Alexandria Venture Investments
    Canaan Partners
    Sofinnova
  • Series B

    $16,000,000

    Series B Investors

    Canaan Partners
    Sofinnova
    Wende Hutton
  • Series Unknown

    $1,745,019

  • Debt Financing

    $1,100,000

  • Series Unknown

    $501,006

Funding info provided by Diffbot.